Cost cutting at Axis-Shield

Related tags Time

In a bid to improve efficiency and reduce costs UK in vitro
diagnostics company Axis-Shield is to shift the manufacture of
certain products from its site in Oslo, Norway to the company's
global headquarters in Dundee, Scotland.

In a bid to improve efficiency and reduce costs UK in vitro​ diagnostics company Axis-Shield is to shift the manufacture of certain products from its site in Oslo, Norway to the company's global headquarters in Dundee, Scotland.

The move will result in the loss of around 40 jobs in Norway, although about 15 new positions will be offered in its expanding Point-of-Care Division, also located in Oslo.

Although the one-off costs associated with the reorganisation are expected to tip the £1 million mark, the company anticipates that ongoing cost savings are expected to be in excess of £1.3 million per annum from 2004 onwards.

Commenting on the reorganisation, Svein Lien, CEO of Axis-Shield said: "We believe our decision represents the best solution for our short and medium term needs. This restructuring means that now Dundee will be the focus for the Laboratory Division and Oslo will be the centre for the Point-of-Care Division."

Turning to Oslo, the company said this week that in parallel to the Scottish move, the company will focus resources in Oslo on the new near-patient system due for launch in 2004.

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...